Daniel Alvarez-Fischer
Daniel Alvarez-Fischer, MD
Clinician scientist
Phone number:+49 451 500 98706

Current Position:

Postdoctoral fellow at the Institute of Neurogenetics and resident at the Department of Psychiatry and Psychotherapy; University of Lübeck

Research focus:

Animal models of neurodegenerative disorders, the role of developmental factors in the etiology of Parkinson disease and their impact on mitochondrial function

Education & Scientific training

Education:

04/1995 – 06/2002 Studies of Medicine at the Philipps University Marburg

04/1997 – 10/2004 MD thesis and related projects; Philipps University Marburg, Institute of Pharmacology and Toxicology (Director: Prof. J. Krieglstein) in the group ‘Reward and Movement Disorders’ (Prof. K. Kuschinsky)
„Mechanismen der Sensibilisierung durch wiederholte Gabe von Kokain als Baustein in der Entwicklung psychischer Abhängigkeit bei der Suchterkrankung am experimentellen Tiermodell der Ratte“ MD (Dr. med.)

Scientific training:

04/1997 – 06/2000 Institute of Pharmacology and Toxicology, Philipps University Marburg, supervised by Prof. K. Kuschinsky
Mechanisms of sensitization to cocaine under aspects of reward and related projects

07/2002 – 02/2006 Department of Neurology Philipps University Marburg (Director: Prof. Wolfgang H. Oertel) in the group of Movement disorders, supervised by PD Dr. A. Hartmann

02/2006 – 06/2009 Pitié-Salpêtrière/INSERM U679 and Collège de France/CNRS UMR8542 in Paris, France, supervised by Prof. A. Hartmann, Prof. A. Prochiantz and Prof. E. C. Hirsch
Role of Engrailed in Parkinson’s disease

07/2009 – 07/2012 Department of Neurology Philipps University Marburg (Director: Prof. Wolfgang H. Oertel) in the group of Movement disorders, supervised by Prof. G. U. Höglinger
Role of electrical activity on survival of DA neurons

08/2012 – present Institute of Neurogenetics (University of Lübeck), supervised by Prof. Dr. C. Klein
Interface of developmental factors and mitochondrial function
Awards
2002 First price at “Route 28” workshop, 2002, (Stem) cell based therapeutic approaches for Parkinson's disease, Frauenchiemsee, Germany

2004 Travel grant from the German Research Foundation (DFG)

2006 Post-doctoral fellowship from the German Academic Exchange Service (DAAD)
Research Funding

Title: “Integrated project LSHM-CT_2003-503330“

Co-Principal Investigator (Principal Investigator: Wolfgang H. Oertel, G. U. Höglinger)
Agency: Europäische Union (EU)
Type: Research Grant
Funding period: 2004-2007
Amount: 60,000 €

Title: “Stem cell therapy in Parkinson’s disease”

Co-Principal Investigator (Principal Investigator: G. U. Höglinger)
Agency: Peter-Hofmann-Foundation
Type: Research Grant
Funding period: January 2005 – December 2006/2007
Amount: 50,000 €

Title: “Translational targets of Engrailed”

Principal Investigator: Daniel Alvarez Fischer
Agency: University Medical Center Giessen and Marburg (UKGM)
Type: Research Grant
Funding period: 2010
Amount: 50,000 €

Title: “Mechanisms of apamine in PD”

Principal Investigator: Daniel Alvarez Fischer
Agency: University Medical Center Giessen and Marburg (UKGM)
Type: Research Grant
Funding period: February 2010-January 2012
Amount: 52,800 €

Title: “Molecular mechanisms modifying disease expression

Principal Investigators: Daniel Alvarez Fischer, Ana Westenberger, Frank Kaiser, Ingrid Bræne
Agency: University of Lübeck, Germany
Type: Application Package (Paketantrag)
Funding period: January-October 2015
Amount: 100,000 €

Publications

Selection of 5 most important publications out of 19;
cumulative impact factor: 113; mean 6

  1. Alvarez-Fischer D, Noelker C, Vulinović F, Grünewald A, Chevarin C, Klein C, Oertel WH, Hirsch EC, Michel PP, Hartmann A. Bee venom and its component apamin as neuroprotective agents in a Parkinson disease mouse model. PLoS One 2013, 8:e61700. 

  2. Alvarez-Fischer D, Noelker C, Grünewald A, Vulinović F, Guerreiro S, Fuchs J, Lu L, Lombès A, Hirsch EC, Oertel WH, Michel PP, Hartmann A. Probenecid potentiates MPTP/MPP+ toxicity by interference with cellular energy metabolism. J Neurochem 2013; 127:782-92. 

  3. Alvarez-Fischer D, Fuchs J, Castagner F, Stettler O, Massiani-Beaudoin O, Moya KL, Bouillot C, Oertel WH, Lombès A, Faigle W, Joshi R, Hartmann A, Prochiantz A. Engrailed proteins protect mouse midbrain dopaminergic neurons against mitochondrial complex I insults and regulate their physiology. Nat neuroscience 2011;14:1260-1266.

  4. Alvarez-Fischer D, Henze C, Strenzke C, Westrich J, Ferger B, Höglinger GU, Oertel WH, Hartmann A. Characterization of the striatal 6-OHDA model of Parkinson’s disease in wild type and α-synuclein-deleted mice. Exp Neurol 2008;210:182-193.

  5. Alvarez-Fischer D, Blessmann G, Trosowski C, Béhé M, Schurrat T, Hartmann A, Oertel WH, Höglinger GU, Höffken H. Quantitative 123I-FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson’s disease. NeuroImage 2007;38:5-12. 

Complete list of publications
  1. Alvarez Fischer D, Schäfer MKH, Ferger B, Groß S, Westermann R, Weihe E, Kuschinsky K. Sensitization to the behavioural effects of cocaine: alterations in tyrosine hydroxylase or endogenous opioid mRNAs are not necessarily involved. Naunyn-Schmiedeberg’s Archives of Pharmacology 2001;363:288-294.

  2. Themann C, Alvarez Fischer D, Groß S, Westermann R, Weihe E, Kuschinsky K, Schäfer MKH, Ferger B. Effect of repeated treatment with high doses of selegiline on behaviour, striatal dopaminergic transmission and tyrosine hydroxylase mRNA levels. Naunyn-Schmiedeberg’s Archives of Pharmacology 2002;365:22-28.

  3. Alvarez Fischer D, Ferger B, Kuschinsky K. Discrimination of morphine- and haloperidol-induced muscular rigidity and akinesia/catalepsy in simple tests in rats. Behav Brain Res 2002;134:317-321.

  4. Lu L, Neff F , Alvarez-Fischer D, Henze C, Oertel WH, Schlegel J and Hartmann A. Gene expression profiling of Lewy body-bearing neurons in Parkinson´s disease. Exp Neurol 2005;195:27-39. 

  5. Lu L, Neff F, Alvarez Fischer D, Henze C, Hirsch EC, Oertel WH, Schlegel J, Hartmann A. Regional vulnerability of mesencephalic dopaminergic neurons in Parkinson´s disease: A human postmortem gene expression profiling study. Neurobiol disease 2006;23:409-421.

  6. Alvarez-Fischer D, Blessmann G, Trosowski C, Béhé M, Schurrat T, Hartmann A, Oertel WH, Höglinger GU, Höffken H. Quantitative 123I-FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson’s disease. NeuroImage 2007;38:5-12. 

  7. Höglinger GU, Breunig JJ, Depboylu C, Rouaux C, Michel PP, Alvarez-Fischer D, Boutillier AL, DeGregori J, Oertel WH, Rakic P, Hirsch EC, Hunot S. The pRb/E2F cell-cycle pathway mediates cell death in Parkinson’s disease. PNAS 2007;104:3585-3590.

  8. Michel PP, Alvarez-Fischer D, Guerreiro S, Hild A, Hartmann A, Hirsch EC. Role of Activity-Dependent Mechanisms in the Control of Dopaminergic Neuron Survival. J Neurochem 2007;101:289-297.

  9. Alvarez-Fischer D, Guerreiro S, Hunot S, Saurini F, Marien M, Sokoloff P, Hirsch EC, Hartmann A, Michel PP. Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid. J Neurochem 2008;107:701-711. 

  10. Salazar J, Mena N, Hunot S, Prigent A, Alvarez-Fischer D, Arredondo M, Duyckaerts C, Sazdovitch V, Zhao L, Garrick LM, Nuñez MT, Garrick MD, Raisman-Vozari R, Hirsch EC. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson’s disease. PNAS 2008;105:18578-18583. 

  11. Dejaegere T, Serneels L, Schäfer MK, Van Biervliet J, Horré K, Depboylu C, Alvarez-Fischer D, Willem M, Haass C, Höglinger GU, D’Hooge R, De Strooper B. Deficiency of Aph1B/C g-Secretase disturbs Nrg1 cleavage and sensorimotor gating which can be reversed with antipsychotic treatment. PNAS 2008;105:9775-9780. 

  12. Alvarez-Fischer D, Henze C, Strenzke C, Westrich J, Ferger B, Höglinger GU, Oertel WH, Hartmann A. Characterization of the striatal 6-OHDA model of Parkinson’s disease in wild type and α-synuclein-deleted mice. Exp Neurol 2008;210:182-193. 

  13. Guerreiro S, Ponceau A, Toulorge D, Martin E, Alvarez-Fischer D, Hirsch EC, Michel PP. Protection of Midbrain Dopaminergic Neurons by the End-Product of Purine Metabolism Uric Acid: Potentiation by Low-Level Depolarization. J Neurochem 2009;109:1118-1128.

  14. Brochard V, Combadière B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S. Brain infiltration of CD4 lymphocytes contributes to neurodegeneration in Parkinson’s disease model. J Clin Invest 2009;119:182-192.

  15. Alvarez-Fischer D, Fuchs J, Castagner F, Stettler O, Massiani-Beaudoin O, Moya KL, Bouillot C, Oertel WH, Lombès A, Faigle W, Joshi R, Hartmann A, Prochiantz A. Engrailed proteins protect mouse midbrain dopaminergic neurons against mitochondrial complex I insults and regulate their physiology. Nat neuroscience 2011;14:1260-1266. 

  16. Ros-Bernal F, Hunot S, Herrero MT, Parnadeau S, Corvol JC, Lu L, Alvarez-Fischer D, Carrillo-de Sauvage MA, Saurini F, Coussieu C, Kinugawa K, Prigent A, Höglinger G, Harnon M, Tronche F, Hirsch EC, Vyas S. Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. PNAS 2011;108:6632-6637.

  17. Alvarez-Fischer D, Oertel WH. Erfolge der Gentherapie rücken in greifbare Nähe. InFo Neurologie & Psychiatrie 2011;4:23.

  18. Alvarez-Fischer D, Grundmann M, Lu L, Samans B, Fritsch B, Moller JC, Schäfer MKH, Hartmann A, Oertel WH, Bandmann O. Prolonged generalized dystonia after chronic cerebellar application of kainic acid. Brain Res 2012;1464:82-88. 

  19. Fuchs J, Stettler O, Alvarez-Fischer D, Prochiantz A, Moya KL, Joshi RL. Engrailed signaling in axon guidance and neuron survival. Eur J Neurosci 2012;35:1837-1845.

< Go back